|
|
Article: New congestive heart failure study findings recently were reported by V. Mitrovic and co-researchers.
- Article from:
- Heart Disease Weekly
- Article date:
- August 9, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
"In the present study, we investigated the efficacy and safety of candesartan cilexetil (candesartan) as ''add-on'' treatment in congestive heart failure (CHF) in daily practice. In this open-label, multicenter study 414 CHF outpatients (NYHA II/III) with left ventricular ejection fraction (LVEF) a parts per thousand currency sign 40% and plasma brain natriuretic peptide (BNP) levels > 200 pg/ml at baseline were enrolled," researchers in Bad Nauheim, Germany report (see also Congestive Heart Failure).
"were treated with standard therapy including at least one angiotensin converting enzyme inhibitor in addition to another CHF drug; 91% of the patients received ...